Press Releases Press Releases Year None20202019201820172016 Date Title November 4, 2020 UNITY Biotechnology, Inc. Reports Third Quarter 2020 Financial Results and Clinical Program Updates SOUTH SAN FRANCISCO, Calif. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2020 . October 12, 2020 UNITY Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema SAN FRANCISCO , Oct. 12, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that the first patient has been dosed in a Phase 1 study of UBX1325 September 15, 2020 UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology - Corporate restructuring to extend cash runway through mid-2022 and key milestones - - UBX1325 to enter clinical development in patients with diabetic macular edema - SAN FRANCISCO, Calif. , Sept. 15, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company September 4, 2020 UNITY Biotechnology to Participate in Upcoming September Investor Conferences SAN FRANCISCO , Sept. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team will participate in the August 31, 2020 UNITY Biotechnology Announces Appointment of Lynne Sullivan as Chief Financial Officer SAN FRANCISCO , Aug. 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced the appointment of Lynne Sullivan to the permanent role of chief August 17, 2020 UNITY Biotechnology Announces 12-week data from UBX0101 Phase 2 Clinical Study in Patients with Painful Osteoarthritis of the Knee UBX0101 failed to meet 12-week primary endpoint Guidance for UNITY’s Bcl-xL inhibitor UBX1325 in retinal disease remains unchanged UNITY to focus senescence programs on ophthalmologic and neurologic diseases in near-term UNITY to hold investor and analyst conference call today, Monday, August 17, August 4, 2020 UNITY Biotechnology Announces $80M Debt Financing From Hercules Capital SAN FRANCISCO , Aug. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that it has entered into a $80 million debt facility with Hercules July 31, 2020 UNITY Biotechnology, Inc. Reports Second Quarter 2020 Financial Results and Clinical Program Updates SOUTH SAN FRANCISCO, Calif. , July 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported financial results for the second quarter ended June July 29, 2020 UPDATE – UNITY Biotechnology, Inc. to Announce Second Quarter 2020 Financial Results SAN FRANCISCO , July 29, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report financial results for the second quarter ended July 24, 2020 UNITY Biotechnology, Inc. to Announce Second Quarter 2020 Financial Results SAN FRANCISCO , July 24, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report financial results for the second quarter ended Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 22
